(redirected from Acute-on-Chronic Liver Failure)
ACLFAcute-on-Chronic Liver Failure
ACLFAdult Congregate Living Facility (retirement home)
ACLFAmerican Constitutional Law Foundation
ACLFAssisted Care Living Facility
ACLFAssociation des Cytogénéticiens de Langue Française (French: French Language Cytogeneticists Association)
ACLFAccess Control List Facility
ACLFAustin City Limits Festival (Austin, Texas)
ACLFAdult Care Living Facility
ACLFAssociation des Chercheurs en Littératures Francophones (French: Association of Researchers in Francophone Literature; est. 2001)
ACLFAustralian Coupe Liberation Front
ACLFAutomatic Channel Locking Filter (Digital Lightwave)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Qiu et al., "Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial," Hepatology, vol.
In our country, hepatitis B virus (HBV) infection is the main cause of acute-on-chronic liver failure (ACLF) [3], the mortality of which is as high as 62.18%-72.3% [4-6].
In the latter clinical constellation, this syndrome has been referred to as acute-on-chronic liver failure (ACLF) [1, 2].
Clinically, acute-on-chronic liver failure (ACLF) is a potentially lethal disease with a higher mortality than acute liver failure (ALF), characterized by the rapid deterioration of liver function [3, 22].
Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis.
"What we've begun to see and to believe more and more is that these patients begin to deteriorate when they develop acute-on-chronic liver failure because of the steady buildup .of toxins in the circulation, which leads to further damage to the liver.
We concentrated on a cohort of patients with hepatitis B-related acute-on-chronic liver failure (HBACLF).
Our previous systematic review and meta-analysis suggested that the performance of MELD score had a higher specificity than the Child-Pugh score for the assessment of prognosis in patients with acute-on-chronic liver failure (3).
These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) to large indications such as acute-on-chronic liver failure (ACLF), and nonalcoholic steatohepatits (NASH)/fibrosis.
Currently, emricasan is in a Phase 2b clinical trial in patients with acute-on-chronic liver failure, as well as a Phase 2 clinical trial in patients with severe alcoholic hepatitis, concluded the company.